Skip to Main Content

For the second time this month, Gilead Sciences (GILD) has lost a bid to invalidate patents owned by the U.S. government for using the Truvada pill to prevent HIV, which has been at the center of controversy over its cost and the extent to which taxpayer dollars funded key research.

The Patent Trial and Appeals Board ruled Gilead failed to demonstrate it was likely to win its argument for overturning two patents held by the Centers for Disease Control and Prevention, which helped fund academic work into HIV prevention that later formed the basis for the pill, also known as PrEP (here is one decision and here is the other). The board issued a similar ruling on Feb. 5 concerning challenges Gilead filed against two other CDC patents (see this and this).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED